Krsnaa Diagnostics IPO

Krsnaa Diagnostics Ltd.

₹13,995 /15 sharesMinimum Investment

Krsnaa Diagnostics IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
4 Aug ‘21 - 6 Aug ‘21₹13,99515₹933 - ₹954
Issue SizeIPO Doc
1213.33Cr
RHP PDF

Subscription Status As on 06 Aug '21, 8:00 PM

  • Retail Individual Investor
    42.04x
  • Non-Institutional Investor
    116.30x
  • Qualified Institutional Buyers
    49.83x
  • Employees
    0.98x

About Krsnaa Diagnostics

Krsnaa Diagnostics Limited is a large and differentiated diagnostic service provider. It provides a range of technology-enabled diagnostic services such as imaging (including radiology), pathology/clinical laboratory, and teleradiology services to public and private hospitals, medical colleges, and community health centers across India. It is the fastest-growing diagnostic chain in India on multiple parameters. The company has an extensive network of integrated diagnostic centers across India primarily in non-metro and lower-tier cities and towns.;
Parent Organisation
Krsnaa Diagnostics Ltd.
Founded
2010
Managing Director
Pallavi Bhatevara

Strengths & Risks

  • Unique and scaled diagnostics company.
  • Brand is associated with providing quality and reliable healthcare services at affordable prices.
  • As of December 31, 2020, its network of diagnostic centers spans 13 states across India in over 1,800 locations.
  • Business model with robust revenue visibility.
  • Well-positioned to capitalize on healthcare spending across public and private sectors.
  • Scalable and agile business model with an efficient cost structure.
  • Consistent track record of financial performance.
  • Ability to maintain cost competitiveness through operating leverage.
  • Experienced promoters and management team supported by a strong employee base.
  • Significant dependence on payments under contracts with public health agencies.
  • Most of its diagnostic centers have been established and are operated under PPP contracts awarded by government agencies through a competitive bidding process. Company may not successfully win these tenders in the future.
  • Continuing impact of the outbreak of the COVID-19.
  • Dependency on its information technology systems and the telecommunication network in India in providing diagnostic services and managing its operations.
  • Prices charged for the diagnostic services are dependent on recommended or mandatory fees fixed under the terms of the agreements entered into with public and private healthcare providers.
  • Delays in the establishment of diagnostic centers resulting in the termination of the agreements or cost overruns.
  • Capital-intensive business.
  • Any failure to comply with the legal and regulatory requirements.
  • Failure to establish and comply with appropriate quality standards when performing imaging, testing, and diagnostics services.
  • Inability to obtain, retain, or renew the required approvals, licenses, registrations, and permits for conducting its business.
  • Highly competitive industry – the diagnostics industry in India.
  • Dependency on third parties for testing equipment and reagents.
  • Any inadequacy in packaging, collection of, or failure, or delay in the delivery of, specimens to its diagnostic centers resulting in the specimens getting compromised or destroyed.

Financials

*All values are in Rs. Cr
No Graph Data To Display
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 3.8.0
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI

ABOUT GROWW